X4 Pharma licenses mavorixafor to Norgine for €28.5M upfront, up to €226M milestones

X4 Pharmaceuticals, Inc

Exclusive license for Europe, Switzerland, UK, Australia, New Zealand; X4 retains rest of world.
X4 receives €28.5M upfront; up to €226M in regulatory, commercial, sales milestones.
Escalating double-digit royalties up to mid-twenties on net sales in licensed territories.
X4 continues Phase 3 4WARD trial in chronic neutropenia; Norgine handles commercialization.
MAA for WHIM syndrome to be submitted to EMA shortly; mavorixafor has Orphan Drug Designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.